- Report
- November 2023
- 140 Pages
Global
From €3410EUR$3,599USD£2,878GBP
- Report
- May 2023
- 140 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- May 2023
- 140 Pages
Global
From €4690EUR$4,949USD£3,958GBP
From €3317EUR$3,500USD£2,799GBP
- Report
- February 2024
- 180 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- February 2024
- 185 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- February 2024
- 172 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- October 2023
- 130 Pages
Europe
From €3790EUR$4,000USD£3,199GBP
- Report
- October 2023
- 177 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- October 2023
- 185 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- October 2023
- 189 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- October 2023
- 171 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- May 2023
- 147 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- January 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
- Report
- July 2023
- 145 Pages
Global
From €2985EUR$3,150USD£2,519GBP
- Report
- January 2024
- 120 Pages
Global
From €7533EUR$7,950USD£6,358GBP
- Report
- January 2024
- 225 Pages
Global
From €7533EUR$7,950USD£6,358GBP
- Report
- May 2023
- 450 Pages
Global
From €4738EUR$5,000USD£3,998GBP
- Report
- January 2022
- 200 Pages
Global
From €9002EUR$9,500USD£7,597GBP
- Report
- December 2023
- 184 Pages
Global
From €2369EUR$2,500USD£1,999GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more